William Conkling is Director of Cyclo Therapeutics, Inc.. Currently has a direct ownership of 33,570 shares of CYTH, which is worth approximately $25,513. The most recent transaction as insider was on Aug 16, 2024, when has been sold 8,731 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 33.6K
35.15% 3M change
1270.76% 12M change
Total Value Held $25,513

WILLIAM CONKLING Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 16 2024
BUY
Grant, award, or other acquisition
-
8,731 Added 20.64%
33,570 Common Stock
Jun 03 2024
BUY
Grant, award, or other acquisition
-
8,594 Added 25.71%
24,839 Common Stock
Feb 13 2024
BUY
Grant, award, or other acquisition
-
6,330 Added 28.04%
16,245 Common Stock
Nov 28 2023
BUY
Grant, award, or other acquisition
-
7,466 Added 42.95%
9,915 Common Stock
Aug 18 2023
BUY
Grant, award, or other acquisition
-
2,449 Added 50.0%
2,449 Common Stock

Also insider at

RFL
Rafael Holdings, Inc. Real Estate
WC

William Conkling

Director
Newark, NJ

Track Institutional and Insider Activities on CYTH

Follow Cyclo Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTH shares.

Notify only if

Insider Trading

Get notified when an Cyclo Therapeutics, Inc. insider buys or sells CYTH shares.

Notify only if

News

Receive news related to Cyclo Therapeutics, Inc.

Track Activities on CYTH